Loading stock data…
ImageneBio, Inc. (IMA)
$5.05+0.12 (+2.43%)
Market ClosedLast close Sep 8
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImageneBio, Inc. in the Healthcare sector is trading at $5.05 with a market capitalization of $61M. Wall Street consensus targets $18.00 (3 analysts), implying a +256.4% move over the next 12 months. The stock is currently 45% below its 52-week high of $9.22, remaining 16.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +256.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 26) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $800,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.08M↓ | -$8.50M↑ | -$26.59M↓ | -$6.00M↑ | -$6.14M |
| Net Income | -$10.62M↓ | -$6.91M↑ | -$24.78M↓ | -$6.08M↓ | -$4.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$61.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.23%
Volume
Today's trading volume
27,534
Recent News
Image Resources NL (ASX:IMA) Is About To Turn The Corner
With the business potentially at an important milestone, we thought we'd take a closer look at Image Resources NL's...
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
IMAX (IMAX) Corporation announces the opening weekend for Amazon (AMZN) / MGM Studies’ “Project Hail Mary,” with IMAX delivering $28M at the global box office. The latest Filmed For IMAX release from Amazon/MGM, “Project Hail Mary” delivered $16.4 million in IMAX at the Domestic box office – 20% of the film’s North American debut on just 1% of screens in the market. “‘Project Hail Mary’ is an excellent film for which Amazon/MGM ran a brilliant campaign, leaning heavily on the power of IMAX as a
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
ImageneBio, Inc. ( NASDAQ:IMA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...